Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648206 | 0.94 | TDP1 (0.40) | TDP1PTGS2ACMSD | |
| SCHEMBL676974 | 0.92 | TDP1 (0.39) | TDP1PTGS2ACMSD | |
| SCHEMBL10793637 | 0.92 | TDP1 (0.39) | TDP1PTGS2ACMSD | |
| SCHEMBL2657767 | 0.85 | — | — | |
| SCHEMBL19584978 | 0.72 | CASP3 (0.38) | F2RL1ACMSD | |
| SCHEMBL115447 | 0.69 | CYP3A4 (0.33) | — | |
| SCHEMBL2658138 | 0.69 | — | — | |
| SCHEMBL5200489 | 0.69 | PLAU (0.34) | — | |
| SCHEMBL11584713 | 0.69 | — | — | |
| SCHEMBL360448 | 0.69 | ACMSD (0.47) | TDP1GRM2PTGS2ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| CN-101610995-A | Novel glucagon receptor antagonists | METABASIS THERAPEUTICS INC (US) | 2009-12-23 | — | — | CN | claimed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | claimed |
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| US-6337377-B1 | CATALYTIC ADDITION POLYMERIZATION OF OLEFIN | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2002-01-08 | — | — | US | claimed |
| US-6127303-A | A COORDINATION CATALYST FOR FORMING TWO ISOTACTIC STEREO-IRREGULAR HOMOPOLYMERS, BASED ON COMPOUNDS OF MAGNESIUM, TITANIUM, HALOGEN, AN ALKYL DIETHER, SILICON ESTER, AND ORGANOALUMINUM; PACKAGING; STRETCHING | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-10-03 | — | — | US | claimed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| US-5510318-A | Herbicidal oxazine ethers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| WO-1994020094-A1 | ANTITUMOR CYCLOPENTANPHTHOQUINONE AND CYCLOPENTANTHRAQUINONE DERIVATIVES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-09-15 | — | — | WO | disclosed |
| US-4282171-A | Phosphorus and sulfur containing amides and thioamides | THE LUBRIZOL CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
| US-4208357-A | Process for preparing phosphorus and sulfur containing amides and thioamides | THE LUBRIZOL CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-4032461-A | PHOSPHORUS AND SULFUR CONTAINING AMIDES AND THIOAMIDES AS LUBRICATING OIL ADDITIVES AND LUBRICATING OIL COMPOSITIONS CONTAINING SAME | THE LUBRIZOL CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4031023-A | Lubricating compositions and methods utilizing hydroxy thioethers | THE LUBRIZOL CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | TDP1 1504/4885GRM2 3873/4885PTGS2 2198/4885 |
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | TDP1 3046/4885GRM2 1240/4885PTGS2 7/4885 |
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | TDP1 3338/4885GRM2 811/4885PTGS2 162/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | TDP1 2038/4885GRM2 4268/4885PTGS2 1905/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | TDP1 4534/4885GRM2 206/4885PTGS2 2521/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | TDP1 2038/4885GRM2 4268/4885PTGS2 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.